Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Cell
Nov 11, 2021 Volume 184 Issue 23 p5691-5838
https://www.cell.com/cell/current

 

Articles
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
Rebecca P. Payne, et al. on behalf of the PITCH Consortium
Open Access
After giving a primary dose, delaying administration of a second dose of BNT162b2 COVID-19 vaccine up to 6–14 weeks continues to provide strong protection and contributes to favorable antibody, B cell, and T cell responses.